Detection of CEA mRNA, p53 and AE1/AE3 in haematoxylin-eosin-negative lymph nodes of early-stage non-small cell lung cancer may improve veracity of N staging and indicate prognosis

Japanese Journal of Clinical Oncology

Volumn 40, Issue 2, 2010, Pages 146-152

  Qiu, Yuan ^a   Yang, Haihong ^a   Chen, Hanzhang ^a   Ge, Linhu ^a   Xu, Xin ^a   Xiong, Xinguo ^a   He, Jianxing ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Carcinoembryonic antigen; Immunohistochemistry; Intracytoplasmic keratins; N staging; Non small cell lung cancer; p53; Quantitative reverse transcription polymerase chain reaction

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CYTOKERATIN AE1; CYTOKERATIN AE3; EOSIN; GEMCITABINE; HEMATOXYLIN; MESSENGER RNA; PROTEIN P53; ANTIPORTER; SLC4A3 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE FREE INTERVAL; EARLY CANCER; FEMALE; FLUORESCENCE ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; MICROMETASTASIS; PREDICTION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; FLUORESCENCE; GENETICS; LABORATORY DIAGNOSIS; LYMPH NODE; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY;

ADULT; AGED; ANTIPORTERS; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; EOSINE YELLOWISH-(YS); FALSE NEGATIVE REACTIONS; FEMALE; FLUORESCENCE; HEMATOXYLIN; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77449133848     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp144     Document Type: Article

References (18)

1. Buccheri G, Ferrigno D. Prognostic value of stage grouping and TNM descriptors in lung cancer. Chest 2000;117:1247-55.
2. Yarbro JW. Introductory remarks to the Conference on Prognostic Factors and Staging in Cancer Management: contributions of artificial neural networks and other statistical methods. Cancer 2001;91(Suppl 8):1593-4.
3. Perng RP, Chen CY, Chang GC, Hsia TC, Hsu NY, Tsai YH, et al. Revisit of 1997 TNM staging system-survival analysis of 1112 lung cancer patients in Taiwan. Jpn J Clin Oncol 2007;37:9-15.
4. Pfannschmidt J, Muley T, Bülzebruck H, Hoffmann H, Dienemann H, et al. Prognostic assessment after surgical resection for non-small cell lung cancer: experiences in 2083 patients. Lung Cancer 2007;55:371-7.
5. 5.Choi YJ, Yun HR, Yoo KE, Kim JH, Nam SJ, Choi YL, et al. Intraoperative examination of sentinel lymph nodes by ultrarapid immunohistochemistry in breast cancer. Jpn J Clin Oncol 2006;36:489-93.
6. Nagatani S, Shimada Y, Li Z, Kaganoi J, Kan T, Maeda M, et al. Validation of intra-operative detection of paratracheal lymph node metastasis using real-time RT-PCR targeting esophageal squamous cell carcinoma. Jpn J Clin Oncol 2003;33:549-55.
7. Fukai R, Sakao Y, Sakuraba M, Oh S, Shiomi K, Sonobe S, et al. The prognostic value of carcinoembryonic antigen in T1N1M0 and T2N1M0 non-small cell carcinoma of the lung. Eur J Cardiothorac Surg 2007;32:440-444.
8. Rena O, Carsana L, Cristina S, Papalia E, Massera F, Errico L, et al. Lymph node isolated tumor cells and micrometastases in pathological stage I non-small cell lung cancer: prognostic significance. Eur J Cardiothorac Surg 2007;32: 863-7.
9. Fijołek J, Wiatr E, Rowińska-Zakrzewska E, Giedronowicz D, Langfort R, Chabowski M, et al. p53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer. Int J Biol Markers 2006;21:81-7.
10. Fong KM, Sekido Y, Gazdar AF, Minna JD. Lung cancer. 9: Molecular biology of lung cancer: clinical implications. Thorax 2003;58:892-900.
11. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-7.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Detection of CEA mRNA Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
13. Marchetti A, Pellegrini C, Buttitta F, Falleni M, Romagnoli S, Felicioni L, et al. Prediction of survival in stage I lung carcinoma patients by telomerase function evaluation. Lab Invest 2002;82:729-36.
14. Chen ZL. An immunohistochemical study of occult micrometastases in regional LNs of patients with stage I non-small cell lung carcinoma (Chinese). Zhonghua Zhong Liu Za Zhi 1992;14:423-6.
15. Vollmer RT, Herdon JE, II, D'Cunha J, Abraham NZ, Solberg J, Fatourechi M, et al. Immunohistochemical detection of occult lymph node metastases in non-small cell lung cancer: anatomical pathology results from Cancer and Leukemia Group B Trial 9761. Clin Cancer Res 2003;9:5630-5.
16. Nosotti M, Falleni M, Palleschi A, Pellegrini C, Alessi F, Bosari S, et al. Quantitative real-time polymerase chain reaction detection of lymph node lung cancer micrometastasis using carcinoembryonic antigen marker. Chest 2005;128:1539-44.
17. Tezel C, Ersev AA, Kiral H, Urek S, Kosar A, Keles M, et al. The impact of immunohistochemical detection of positive LNs in early stage lung cancer. Thorac Cardiovasc Surg 2006;54:124-8.
18. Wang WB, Cui YG, Yao SY. Message RNA expression of LUNX, CK19 and CEA genes in NSCLC with micrometastasis in LNs (Chinese). Zhonghua Zhong Liu Za Zhi 2008;30:121-4.